tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Royalty Pharma raises FY25 portfolio receipts view to $3.2B-$3.25B
PremiumThe FlyRoyalty Pharma raises FY25 portfolio receipts view to $3.2B-$3.25B
5d ago
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
Premium
The Fly
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
6d ago
Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
Premium
The Fly
Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
1M ago
Royalty Pharma Completes $2 Billion Senior Notes Offering
PremiumCompany AnnouncementsRoyalty Pharma Completes $2 Billion Senior Notes Offering
2M ago
Royalty Pharma: Strong Performance and Promising Outlook Justify Buy Rating
Premium
Ratings
Royalty Pharma: Strong Performance and Promising Outlook Justify Buy Rating
2M ago
Royalty Pharma ‘on track’ to deliver portfolio receipts of $4.7B by 2030
Premium
The Fly
Royalty Pharma ‘on track’ to deliver portfolio receipts of $4.7B by 2030
2M ago
Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
PremiumMarket NewsRoyalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen
3M ago
Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra
Premium
The Fly
Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra
3M ago
BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
Premium
The Fly
BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100